

**TDMS No.** 99037 - 06

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS  
ABRIDGED) (a)**

**Date Report Requested:** 08/11/2010

**Test Type:** CHRONIC

alpha/beta Thujone mixture

**Time Report Requested:** 13:12:57

**Route:** GAVAGE

**CAS Number:** THUJONEMIXAB

**First Dose M/F:** 06/30/03 / 06/30/03

**Species/Strain:** MICE/B6C3F1

**Lab:** SRI

F2\_M3

**C Number:** C99037B  
**Lock Date:** 11/20/2006  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** 25022 ACCK  
25019 MSAC  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.2.0

25021 TSAC

25020 NATD

25018 DACC

Test Type: CHRONIC

alpha/beta Thujone mixture  
CAS Number: THUJONEMIXAB

Time Report Requested: 13:12:57

Route: GAVAGE

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
------------------	---------	---------	---------	----------	----------

**Disposition Summary**

<b>Animals Initially In Study</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>
<b>Early Deaths</b>					
<b>Dosing Accident</b>		<b>1</b>			
<b>Moribund Sacrifice</b>	<b>3</b>		<b>4</b>	<b>4</b>	
<b>Natural Death</b>	<b>7</b>	<b>7</b>	<b>5</b>	<b>9</b>	<b>36</b>
<b>Survivors</b>					
<b>Natural Death</b>					<b>1</b>
<b>Terminal Sacrifice</b>	<b>40</b>	<b>42</b>	<b>41</b>	<b>37</b>	<b>13</b>
<b>Animals Examined Microscopically</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)	(50)
Intestine Small, Duodenum	(48)	(46)	(50)	(46)	(48)
Adenoma			1 (2%)	1 (2%)	
Carcinoma			1 (2%)		
Intestine Small, Ileum	(50)	(48)	(48)	(47)	(49)
Carcinoma			1 (2%)	1 (2%)	
Intestine Small, Jejunum	(48)	(46)	(49)	(46)	(43)
Carcinoma		2 (4%)	2 (4%)	1 (2%)	
Leiomyosarcoma	1 (2%)				
Liver	(50)	(50)	(50)	(50)	(50)
Cholangioma				1 (2%)	
Hemangiosarcoma	2 (4%)	3 (6%)	2 (4%)	1 (2%)	
Hepatoblastoma	2 (4%)	3 (6%)	1 (2%)	2 (4%)	
Hepatoblastoma, Multiple	1 (2%)				
Hepatocellular Adenoma	10 (20%)	15 (30%)	16 (32%)	16 (32%)	6 (12%)
Hepatocellular Adenoma, Multiple	14 (28%)	8 (16%)	14 (28%)	12 (24%)	7 (14%)
Hepatocellular Carcinoma	13 (26%)	18 (36%)	15 (30%)	13 (26%)	2 (4%)
Hepatocellular Carcinoma, Multiple	3 (6%)	8 (16%)	8 (16%)	3 (6%)	3 (6%)
Hepatocholangioma	1 (2%)				
Leiomyosarcoma, Metastatic, Stomach, Glandular				1 (2%)	
Mast Cell Tumor Malignant		2 (4%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Mesentery	(4)	(4)	(3)	(7)	(3)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (33%)		
Hemangioma				1 (14%)	
Hemangiosarcoma		1 (25%)			
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum	1 (25%)				
Leiomyosarcoma, Metastatic, Stomach, Glandular				1 (14%)	
Sarcoma		1 (25%)			
Pancreas	(50)	(50)	(50)	(50)	(50)
Hepatoblastoma, Metastatic, Liver				1 (2%)	
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum	1 (2%)				
Leiomyosarcoma, Metastatic, Stomach, Glandular				1 (2%)	
Sarcoma, Metastatic, Mesentery		1 (2%)			
Salivary Glands	(50)	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)	(50)
Squamous Cell Carcinoma				1 (2%)	
Squamous Cell Papilloma			1 (2%)	1 (2%)	1 (2%)
Stomach, Glandular	(50)	(50)	(50)	(49)	(50)
Leiomyosarcoma				1 (2%)	
Mast Cell Tumor Malignant				1 (2%)	
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)	
Tongue	(1)	(0)	(0)	(1)	(0)
Fibroma	1 (100%)				
<b>CARDIOVASCULAR SYSTEM</b>					
Heart	(50)	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			2 (4%)		
Hepatoblastoma, Metastatic, Liver				1 (2%)	
Schwannoma Malignant				1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture  
CAS Number: THUJONEMIXAB

Time Report Requested: 13:12:57

Route: GAVAGE

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
<b>ENDOCRINE SYSTEM</b>					
Adrenal Cortex	(50)	(50)	(50)	(50)	(50)
Leiomyosarcoma, Metastatic, Stomach, Glandular				1 (2%)	
Subcapsular, Adenoma	2 (4%)	4 (8%)	2 (4%)	5 (10%)	
Adrenal Medulla	(49)	(49)	(50)	(50)	(50)
Pheochromocytoma Malignant	1 (2%)				
Bilateral, Pheochromocytoma Benign		1 (2%)			
Islets, Pancreatic	(50)	(50)	(50)	(50)	(50)
Adenoma	4 (8%)	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Adenoma, Multiple		1 (2%)			
Parathyroid Gland	(43)	(48)	(47)	(46)	(48)
Pituitary Gland	(48)	(50)	(48)	(49)	(49)
Pars Distalis, Adenoma		1 (2%)			
Thyroid Gland	(49)	(50)	(50)	(49)	(50)
Follicular Cell, Adenoma	1 (2%)			1 (2%)	
Follicular Cell, Carcinoma	1 (2%)				
<b>GENERAL BODY SYSTEM</b>					
Tissue NOS	(1)	(1)	(1)	(1)	(0)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (100%)		
Hemangiosarcoma		1 (100%)			
Hepatocellular Carcinoma, Metastatic, Liver	1 (100%)				
<b>GENITAL SYSTEM</b>					
Epididymis	(50)	(50)	(50)	(50)	(50)
Penis	(1)	(0)	(0)	(1)	(0)
Preputial Gland	(49)	(49)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)			
Prostate	(49)	(50)	(50)	(50)	(50)
Seminal Vesicle	(50)	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Leiomyosarcoma, Metastatic, Stomach, Glandular				1 (2%)	
Sarcoma, Metastatic, Mesentery		1 (2%)			
Testes	(50)	(50)	(50)	(50)	(50)
Interstitial Cell, Adenoma	1 (2%)	1 (2%)	1 (2%)		
<b>HEMATOPOIETIC SYSTEM</b>					
Bone Marrow	(50)	(50)	(50)	(50)	(50)
Hemangiosarcoma				1 (2%)	
Mast Cell Tumor Malignant		2 (4%)			
Lymph Node	(3)	(0)	(1)	(1)	(0)
Hepatoblastoma, Metastatic, Liver				1 (100%)	
Mediastinal, Hepatoblastoma, Metastatic, Liver				1 (100%)	
Thoracic, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (33%)				
Lymph Node, Mandibular	(47)	(49)	(46)	(47)	(44)
Mast Cell Tumor Malignant		1 (2%)			
Lymph Node, Mesenteric	(49)	(48)	(47)	(47)	(50)
Leiomyosarcoma, Metastatic, Stomach, Glandular				1 (2%)	
Plasma Cell Tumor Malignant	1 (2%)				
Spleen	(50)	(50)	(50)	(49)	(50)
Hemangiosarcoma	1 (2%)		3 (6%)		
Mast Cell Tumor Malignant		2 (4%)			
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)	
Thymus	(44)	(43)	(44)	(40)	(49)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)				
<b>INTEGUMENTARY SYSTEM</b>					
Skin	(50)	(50)	(50)	(50)	(50)
Keratoacanthoma					1 (2%)
Mast Cell Tumor Malignant		1 (2%)			
Subcutaneous Tissue, Fibroma				1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Subcutaneous Tissue, Hemangiosarcoma		1 (2%)		1 (2%)	
Subcutaneous Tissue, Osteosarcoma, Metastatic, Uncertain Primary Site		1 (2%)			
<b>MUSCULOSKELETAL SYSTEM</b>					
Bone	(50)	(50)	(50)	(49)	(50)
Osteoma	1 (2%)				
Skeletal Muscle	(2)	(1)	(3)	(1)	(0)
Hemangiosarcoma	2 (100%)		1 (33%)		
Hepatoblastoma, Metastatic, Liver Sarcoma		1 (100%)		1 (100%)	
<b>NERVOUS SYSTEM</b>					
Brain	(50)	(50)	(50)	(50)	(50)
<b>RESPIRATORY SYSTEM</b>					
Lung	(50)	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	7 (14%)	3 (6%)	8 (16%)	6 (12%)	6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple		2 (4%)			
Alveolar/Bronchiolar Carcinoma	6 (12%)	4 (8%)	6 (12%)	3 (6%)	1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple			3 (6%)	1 (2%)	2 (4%)
Hepatoblastoma, Metastatic, Liver				1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	4 (8%)	8 (16%)	9 (18%)	5 (10%)	1 (2%)
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum	1 (2%)				
Schwannoma Malignant, Metastatic, Heart				1 (2%)	
Nose	(50)	(50)	(50)	(50)	(50)
Fibroma			1 (2%)		
<b>SPECIAL SENSES SYSTEM</b>					

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Eye	(50)	(50)	(50)	(50)	(50)
Harderian Gland	(50)	(50)	(50)	(50)	(49)
Adenoma	8 (16%)	8 (16%)	4 (8%)	1 (2%)	2 (4%)
Carcinoma	2 (4%)	2 (4%)	3 (6%)	1 (2%)	
Bilateral, Adenoma		1 (2%)			
<b>URINARY SYSTEM</b>					
Kidney	(50)	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)		2 (4%)		
Hepatoblastoma, Metastatic, Liver				1 (2%)	
Renal Tubule, Adenoma			1 (2%)		
Urethra	(0)	(1)	(0)	(0)	(0)
Urinary Bladder	(50)	(50)	(50)	(50)	(50)
<b>SYSTEMIC LESIONS</b>					
Multiple Organ	*(50)	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)	1 (2%)			
Lymphoma Malignant	4 (8%)	2 (4%)	7 (14%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

---

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
------------------	---------	---------	---------	----------	----------

---

**Tumor Summary for Males**

Total Animals with Primary Neoplasms (b)	45	45	46	42	19
Total Primary Neoplasms	91	103	103	80	33
Total Animals with Benign Neoplasms	32	32	36	35	16
Total Benign Neoplasms	50	46	50	47	25
Total Animals with Malignant Neoplasms	30	33	38	27	7
Total Malignant Neoplasms	41	57	53	33	8
Total Animals with Metastatic Neoplasms	6	10	11	9	1
Total Metastatic Neoplasms	11	11	15	21	1
Total Animals with Malignant Neoplasms Uncertain Primary Site		1			
Total Animals with Neoplasms Uncertain- Benign or Malignant					
Total Uncertain Neoplasms					

---

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors



Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
--------------------	---------	---------	---------	----------	----------

**Disposition Summary**

Animals Initially In Study	50	50	50	50	50
Early Deaths					
Accidentally Killed	2				1
Dosing Accident		6			4
Moribund Sacrifice	4	4	2	3	8
Natural Death	7	6	8	6	37
Survivors					
Natural Death			1		
Terminal Sacrifice	37	33	39	41	
Animals Examined Microscopically	50	49	50	50	50

## ALIMENTARY SYSTEM

Esophagus	(50)	(48)	(49)	(50)	(50)
Gallbladder	(43)	(39)	(43)	(46)	(46)
Intestine Large, Cecum	(48)	(46)	(46)	(49)	(49)
Intestine Small, Duodenum	(46)	(44)	(45)	(46)	(48)
Adenoma				1 (2%)	
Leiomyosarcoma		1 (2%)			
Intestine Small, Ileum	(48)	(47)	(45)	(49)	(48)
Intestine Small, Jejunum	(47)	(47)	(45)	(48)	(47)
Leiomyosarcoma		1 (2%)		1 (2%)	
Liver	(50)	(49)	(49)	(50)	(50)
Hemangiosarcoma	1 (2%)		1 (2%)		
Hepatocellular Adenoma	10 (20%)	3 (6%)	9 (18%)	5 (10%)	
Hepatocellular Adenoma, Multiple	3 (6%)	1 (2%)	2 (4%)	3 (6%)	
Hepatocellular Carcinoma	2 (4%)	7 (14%)	3 (6%)		
Hepatocellular Carcinoma, Multiple	1 (2%)				
Plasma Cell Tumor Malignant	1 (2%)				
Mesentery	(10)	(6)	(5)	(6)	(0)
Hemangioma			1 (20%)		
Hemangiosarcoma			1 (20%)		
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum				1 (17%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Schwannoma Malignant, Metastatic, Skin	1 (10%)				
Pancreas	(48)	(49)	(48)	(50)	(50)
Sarcoma, Metastatic, Skin		1 (2%)			
Salivary Glands	(49)	(48)	(49)	(50)	(50)
Stomach, Forestomach	(50)	(49)	(48)	(50)	(50)
Hemangioma			1 (2%)		
Stomach, Glandular	(48)	(49)	(47)	(48)	(50)
Tongue	(0)	(0)	(0)	(0)	(1)

## CARDIOVASCULAR SYSTEM

Heart	(50)	(49)	(50)	(50)	(50)
-------	------	------	------	------	------

## ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(49)	(49)	(50)	(50)
Adenoma	1 (2%)				
Plasma Cell Tumor Malignant	1 (2%)				
Adrenal Medulla	(50)	(47)	(46)	(48)	(49)
Pheochromocytoma Benign		1 (2%)	1 (2%)		
Islets, Pancreatic	(48)	(49)	(48)	(50)	(50)
Adenoma	1 (2%)	1 (2%)			
Parathyroid Gland	(45)	(42)	(46)	(47)	(49)
Pituitary Gland	(49)	(48)	(48)	(49)	(47)
Pars Distalis, Adenoma	2 (4%)	3 (6%)	3 (6%)		
Pars Intermedia, Adenoma			1 (2%)		
Pars Intermedia, Carcinoma				1 (2%)	
Thyroid Gland	(50)	(48)	(48)	(49)	(49)
Follicular Cell, Adenoma			1 (2%)		

## GENERAL BODY SYSTEM

Tissue NOS	(1)	(0)	(0)	(0)	(0)
Plasma Cell Tumor Malignant	1 (100%)				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
--------------------	---------	---------	---------	----------	----------

## GENITAL SYSTEM

Clitoral Gland	(48)	(46)	(48)	(49)	(47)
Ovary	(48)	(47)	(49)	(48)	(50)
Choriocarcinoma	1 (2%)				
Cystadenoma	2 (4%)		4 (8%)	3 (6%)	
Granulosa Cell Tumor Benign		1 (2%)			
Hemangiosarcoma			1 (2%)		
Luteoma			2 (4%)	1 (2%)	
Plasma Cell Tumor Malignant	1 (2%)				
Uterus	(50)	(49)	(50)	(50)	(50)
Leiomyosarcoma		1 (2%)		1 (2%)	
Polyp Stromal	1 (2%)	1 (2%)	1 (2%)		
Sarcoma Stromal		1 (2%)			

## HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(49)	(49)	(50)	(50)
Hemangiosarcoma	1 (2%)		1 (2%)		
Mast Cell Tumor Benign				1 (2%)	
Plasma Cell Tumor Malignant	1 (2%)				
Lymph Node	(6)	(3)	(3)	(1)	(0)
Plasma Cell Tumor Malignant	1 (17%)				
Bronchial, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (33%)			
Mediastinal, Plasma Cell Tumor Malignant	1 (17%)				
Lymph Node, Mandibular	(48)	(46)	(45)	(48)	(49)
Plasma Cell Tumor Malignant	1 (2%)				
Lymph Node, Mesenteric	(46)	(49)	(46)	(48)	(47)
Plasma Cell Tumor Malignant	1 (2%)				
Spleen	(50)	(49)	(48)	(50)	(50)
Hemangiosarcoma	1 (2%)		2 (4%)		
Plasma Cell Tumor Malignant	1 (2%)				
Thymus	(46)	(45)	(46)	(48)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Fibrosarcoma, Metastatic, Skin			1 (2%)		
<b>INTEGUMENTARY SYSTEM</b>					
Mammary Gland	(50)	(49)	(50)	(50)	(50)
Adenoma				1 (2%)	
Carcinoma	1 (2%)	1 (2%)			
Skin	(50)	(49)	(50)	(50)	(50)
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum		1 (2%)			
Subcutaneous Tissue, Fibrosarcoma	2 (4%)	4 (8%)	1 (2%)		
Subcutaneous Tissue, Hemangiosarcoma	1 (2%)		1 (2%)		
Subcutaneous Tissue, Sarcoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)	
Subcutaneous Tissue, Schwannoma Malignant	1 (2%)			1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>					
Bone	(50)	(49)	(50)	(50)	(50)
Skeletal Muscle	(3)	(2)	(0)	(0)	(0)
Rhabdomyosarcoma	1 (33%)				
Sarcoma		2 (100%)			
Schwannoma Malignant, Metastatic, Skin	1 (33%)				
<b>NERVOUS SYSTEM</b>					
Brain	(50)	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Pituitary Gland				1 (2%)	
Cranial Nerve, Schwannoma Malignant	1 (2%)				
<b>RESPIRATORY SYSTEM</b>					
Lung	(50)	(49)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	2 (4%)	4 (8%)	2 (4%)	2 (4%)	
Alveolar/Bronchiolar Adenoma, Multiple	1 (2%)				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Alveolar/Bronchiolar Carcinoma	1 (2%)	3 (6%)	2 (4%)	1 (2%)	
Alveolar/Bronchiolar Carcinoma, Multiple			1 (2%)		
Carcinoma, Metastatic, Harderian Gland			1 (2%)	1 (2%)	
Carcinoma, Metastatic, Uncertain Primary Site				1 (2%)	
Fibrosarcoma, Metastatic, Skin	1 (2%)		1 (2%)		
Plasma Cell Tumor Malignant	1 (2%)				
Nose	(50)	(49)	(50)	(50)	(50)
Pleura	(0)	(0)	(0)	(0)	(4)
Trachea	(50)	(49)	(50)	(50)	(50)
<b>SPECIAL SENSES SYSTEM</b>					
Eye	(50)	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland			1 (2%)	1 (2%)	
Harderian Gland	(50)	(49)	(50)	(49)	(50)
Adenoma	5 (10%)	1 (2%)	5 (10%)	9 (18%)	1 (2%)
Carcinoma	1 (2%)	2 (4%)	4 (8%)	3 (6%)	
<b>URINARY SYSTEM</b>					
Kidney	(50)	(49)	(49)	(50)	(50)
Plasma Cell Tumor Malignant	1 (2%)				
Urinary Bladder	(50)	(49)	(49)	(50)	(50)
Plasma Cell Tumor Malignant	1 (2%)				
<b>SYSTEMIC LESIONS</b>					
Multiple Organ	*(50)	*(49)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	2 (4%)	2 (4%)		4 (8%)	
Lymphoma Malignant	6 (12%)	9 (18%)	13 (26%)	13 (26%)	
Mesothelioma Malignant			1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

---

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
--------------------	---------	---------	---------	----------	----------

---

**Tumor Summary for Females**

Total Animals with Primary Neoplasms (b)	35	31	36	34	1
Total Primary Neoplasms	66	51	66	52	1
Total Animals with Benign Neoplasms	22	14	23	19	1
Total Benign Neoplasms	28	16	33	26	1
Total Animals with Malignant Neoplasms	19	25	25	24	
Total Malignant Neoplasms	38	35	33	26	
Total Animals with Metastatic Neoplasms	2	3	2	4	
Total Metastatic Neoplasms	3	3	4	5	
Total Animals with Malignant Neoplasms Uncertain Primary Site				1	
Total Animals with Neoplasms Uncertain- Benign or Malignant					
Total Uncertain Neoplasms					

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors